Part 1 of 2...

Vogel G.
Tau protein mutations confirmed as neuron killers.
Science. 1998 Jun 5; 280(5369): 1524-1525. No abstract available.
PMID: 9644015; UI: 98299178.

 Caligiuri MP, et al.           
Scaling of movement velocity: a measure of neuromotor retardation in
individuals with psychopathology.
Psychophysiology. 1998 Jul; 35(4): 431-437.
PMID: 9643057; UI: 98307027.

 Kesselring J.           
[No title available].
Schweiz Med Wochenschr. 1998 May 16; 128(20): 784-789. German.
PMID: 9642754; UI: 98306722.

 Nakatome M, et al.           
Detection and Analysis of Four Polymorphic Markers at the Human Monoamine
Oxidase (MAO) Gene in Japanese Controls and Patients with Parkinson's Disease.
Biochem Biophys Res Commun. 1998 Jun 18; 247(2): 452-456.
PMID: 9642149.

 Sagara Y, et al.           
Cellular mechanisms of resistance to chronic oxidative stress.
Free Radic Biol Med. 1998 Jun; 24(9): 1375-1389.
PMID: 9641255; UI: 98302957.

 Henry B, et al.           
Characterization of enhanced behavioral responses to l-DOPA following repeated
administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's
disease.
Exp Neurol. 1998 Jun; 151(2): 334-342.
PMID: 9628768; UI: 98292485.

 Leff SE, et al.           
In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L
gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine
hydroxylase.
Exp Neurol. 1998 Jun; 151(2): 249-264.
PMID: 9628761; UI: 98292478.

 Borlongan CV, et al.           
Intrastriatal transplantation of rat adrenal chromaffin cells seeded on
microcarrier beads promote long-term functional recovery in hemiparkinsonian
rats.
Exp Neurol. 1998 Jun; 151(2): 203-214.
PMID: 9628755; UI: 98292472.

 Emond P, et al.           
Toxicity, mutagenicity, and behavioral effects of beta-CIT, a ligand for
dopamine transporter exploration by SPECT.
Nucl Med Biol. 1998 May; 25(4): 405-409.
PMID: 9639303; UI: 98301174.

 Dooley M, et al.           
Pramipexole. A review of its use in the management of early and advanced
Parkinson's disease.
Drugs Aging. 1998 Jun; 12(6): 495-514.
PMID: 9638397; UI: 98302253.

 Veldman BA, et al.           
Genetic and environmental risk factors in Parkinson's disease.
Clin Neurol Neurosurg. 1998 Mar; 100(1): 15-26.
PMID: 9637199; UI: 98299269.

 Ara J, et al.           
Inactivation of tyrosine hydroxylase by nitration following exposure to
peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Proc Natl Acad Sci U S A. 1998 Jun 23; 95(13): 7659-7663.
PMID: 9636206.

 Walker DG, et al.           
Expression of the proto-oncogene ret, a component of the GDNF receptor
complex, persists in human substantia nigra neurons in Parkinson's disease.
Brain Res. 1998 May 11; 792(2): 207-217.
PMID: 9593897; UI: 98256157.

 Van Muiswinkel FL, et al.           
Sustained pharmacological inhibition of nitric oxide synthase does not affect
the survival of intrastriatal rat fetal mesencephalic transplants.
Brain Res. 1998 May 4; 792(1): 48-58.
PMID: 9593818; UI: 98256136.

 Rocca WA, et al.           
Validation of a telephone questionnaire for Parkinson's disease.
J Clin Epidemiol. 1998 Jun; 51(6): 517-523.
PMID: 9636001; UI: 98297924.

 Perrine DM.           
N-methyl-(R)-salsolinol and Parkinson's disease.
Lancet. 1998 Jun 13; 351(9118): 1818. No abstract available.
PMID: 9635986; UI: 98297909.

 Doudet DJ, et al.           
6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced
parkinsonism in monkeys.
Synapse. 1998 Jul; 29(3): 225-232.
PMID: 9635892; UI: 98297815.

 Kakinuma S, et al.           
Muscle weakness in Parkinson's disease: isokinetic study of the lower limbs.
Eur Neurol. 1998; 39(4): 218-222.
PMID: 9635472; UI: 98297395.

 Imao K, et al.           
Free radical scavenging activity of fermented papaya preparation and its
effect on lipid peroxide level and superoxide dismutase activity in iron-
induced epileptic foci of rats.
Biochem Mol Biol Int. 1998 Jun; 45(1): 11-23.
PMID: 9635126; UI: 98298865.

 Lorigados L, et al.           
[No title available].
Rev Neurol. 1998 May; 26(153): 744-748. Spanish.
PMID: 9634658; UI: 98298397.

 Vatassery GT, et al.           
Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP
study. Parkinson Study Group.
Neurology. 1998 Jun; 50(6): 1900-1902.
PMID: 9633757; UI: 98295514.

 Maricle RA, et al.           
Mood response to levodopa infusion in early Parkinson's disease.
Neurology. 1998 Jun; 50(6): 1890-1892.
PMID: 9633754; UI: 98295511.

 Vickrey BG, et al.           
Practice styles of US compared to UK neurologists.
Neurology. 1998 Jun; 50(6): 1661-1668.
PMID: 9633708; UI: 98295465.

 Hocherman S, et al.           
Visuomotor control abnormalities in patients with unilateral parkinsonism.
Neurology. 1998 Jun; 50(6): 1648-1654.
PMID: 9633706; UI: 98295463.

Schneider JS, et al.           
Parkinson's disease: improved function with GM1 ganglioside treatment in a
randomized placebo-controlled study.
Neurology. 1998 Jun; 50(6): 1630-1636.
PMID: 9633704; UI: 98295461.

 Jenner PG, et al.           
Levodopa neurotoxicity: experimental studies versus clinical relevance.
Neurology. 1998 Jun; 50(6 Suppl 6): S39-S43. Review.
PMID: 9633686; UI: 98295443.

 Lieberman A.           
Managing the neuropsychiatric symptoms of Parkinson's disease.
Neurology. 1998 Jun; 50(6 Suppl 6): S33-S38. Review.
PMID: 9633685; UI: 98295442.

 Martinez-Martin P, et al.           
Extending levodopa action: COMT inhibition.
Neurology. 1998 Jun; 50(6 Suppl 6): S27-S32. Review.
PMID: 9633684; UI: 98295441.

 Poewe W.           
Adjuncts to levodopa therapy: dopamine agonists.
Neurology. 1998 Jun; 50(6 Suppl 6): S23-S26. Review.
PMID: 9633683; UI: 98295440.

 Silver DE, et al.           
Initiating therapy for Parkinson's disease.
Neurology. 1998 Jun; 50(6 Suppl 6): S18-S22. Review.
PMID: 9633682; UI: 98295439.

 Capildeo R.           
Implications of the 5-year CR FIRST trial. Sinemet CR Five-Year International
Response Fluctuation Study.
Neurology. 1998 Jun; 50(6 Suppl 6): S15-S17.
PMID: 9633681; UI: 98295438.

 Koller WC, et al.           
Mechanism of action of dopaminergic agents in Parkinson's disease.
Neurology. 1998 Jun; 50(6 Suppl 6): S11-S14. Review.
PMID: 9633680; UI: 98295437.

 Tolosa E, et al.           
History of levodopa and dopamine agonists in Parkinson's disease treatment.
Neurology. 1998 Jun; 50(6 Suppl 6): S2-S10.
PMID: 9633679; UI: 98295436.

 Koller WC, et al.           
Current and emerging drug therapies in the management of Parkinson's disease.
Neurology. 1998 Jun; 50(6 Suppl 6): S1. No abstract available.
PMID: 9633678; UI: 98295435.

 Aubin L.           
[Parkinson's disease].
Soins. 1998 Apr; 624: XVII-XVIII. French. No abstract available.
PMID: 9633466; UI: 98297122.

 Hayes AE, et al.           
Toward a functional analysis of the basal ganglia.
J Cogn Neurosci. 1998 Mar; 10(2): 178-198.
PMID: 9555106; UI: 98223722.

 Zawada WM, et al.           
Growth factors improve immediate survival of embryonic dopamine neurons after
transplantation into rats.
Brain Res. 1998 Mar 9; 786(1-2): 96-103.
PMID: 9554968; UI: 98223483.

 Riekkinen P Jr, et al.           
Hippocampal atrophy is related to impaired memory, but not frontal functions
in non-demented Parkinson's disease patients.
Neuroreport. 1998 May 11; 9(7): 1507-1511.
PMID: 9631457; UI: 98294918.

 Liska DJ.           
The Detoxification Enzyme Systems.
Altern Med Rev. 1998 Jun; 3(3): 187-198.
PMID: 9630736.

 Mirel DB, et al.           
Characterization of the human mitochondrial aconitase gene.
Gene. 1998 Jun 15; 213(1-2): 205-218.
PMID: 9630632.

 Schapira AHV.           
Human complex I defects in neurodegenerative diseases.
Biochim Biophys Acta. 1998 May 6; 1364(2): 261-270.
PMID: 9593927; UI: 98256015.

 Reed LA, et al.           
The neuropathology of a chromosome 17-linked autosomal dominant parkinsonism
and dementia ("pallido-ponto-nigral degeneration").
J Neuropathol Exp Neurol. 1998 Jun; 57(6): 588-601.
PMID: 9630238; UI: 98292192.

 Jeon BS, et al.           
Dopamine transporter density measured by [123I]beta-CIT single-photon emission
computed tomography is normal in dopa-responsive dystonia.
Ann Neurol. 1998 Jun; 43(6): 792-800.
PMID: 9629849; UI: 98291801.

 Muenter MD, et al.           
Hereditary form of parkinsonism--dementia.
Ann Neurol. 1998 Jun; 43(6): 768-781.
PMID: 9629847; UI: 98291799.

 [No authors listed]           
Tolcapone for Parkinson's disease.
Med Lett Drugs Ther. 1998 Jun 5; 40(1028): 60-61. No abstract available.
PMID: 9629124; UI: 98292769.

 Lavedan C, et al.           
Contig map of the Parkinson's disease region on 4q21-q23.
DNA Res. 1998 Feb 28; 5(1): 19-23.
PMID: 9628579; UI: 98290543.

 Schwarz SC, et al.           
Effects of macrophage migration inhibitory factor and macrophage migration
stimulatory factor on function and survival of foetal dopaminergic grafts in
the 6-hydroxydopamine rat model of Parkinson's disease.
Exp Brain Res. 1998 May; 120(1): 95-103.
PMID: 9628407; UI: 98290371.

 Katsunuma H, et al.           
Treatment of insomnia by concomitant therapy with Zopiclone and Aniracetam in
patients with cerebral infarction, cerebroatrophy, Alzheimer's disease and
Parkinson's disease.
Psychiatry Clin Neurosci. 1998 Apr; 52(2): 198-200.
PMID: 9628149; UI: 98290113.

 Hoogendijk WJ, et al.           
Depression in Parkinson's disease is not accompanied by more corticotropin-
releasing hormone expressing neurons in the hypothalamic paraventricular
nucleus.
Biol Psychiatry. 1998 Jun 15; 43(12): 913-917.
PMID: 9627747; UI: 98291217.

 Hierholzer J, et al.           
Loss of dopamine-D2 receptor binding sites in parkinsonian plus syndromes.
J Nucl Med. 1998 Jun; 39(6): 954-960.
PMID: 9627325; UI: 98289014.

 Trepanier L, et al.           
Hemisphere-specific cognitive and motor changes after unilateral
posteroventral pallidotomy.
Arch Neurol. 1998 Jun; 55(6): 881-883. No abstract available.
PMID: 9626783; UI: 98288472.

 Haavik J, et al.           
Tyrosine hydroxylase and Parkinson's disease.
Mol Neurobiol. 1998 Jun; 16(3): 285-309.
PMID: 9626667; UI: 98289969.

 Iacopino DG, et al.           
Pallidotomy improves quality of life in selected parkinsonian patients: an
Italian report.
Funct Neurol. 1998 Apr; 13(2): 105-115.
PMID: 9626595; UI: 98289897.

 Roth J, et al.           
Apomorphine does not influence olfactory thresholds in Parkinson's disease.
Funct Neurol. 1998 Apr; 13(2): 99-103.
PMID: 9626594; UI: 98289896.

 Smithson F, et al.           
Performance on clinical tests of balance in Parkinson's disease.
Phys Ther. 1998 Jun; 78(6): 577-592.
PMID: 9626270; UI: 98289510.

 Bridgewater KJ, et al.           
Trunk muscle performance in early Parkinson's disease.
Phys Ther. 1998 Jun; 78(6): 566-576.
PMID: 9626269; UI: 98289509.

 Baraldi PG, et al.           
Design, synthesis, and biological evaluation of a second generation of
pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A
adenosine receptor antagonists.
J Med Chem. 1998 Jun 4; 41(12): 2126-2133.
PMID: 9622554; UI: 98285678.

 Castro ME, et al.           
5-HT1B receptor binding in degenerative movement disorders.
Brain Res. 1998 Apr 20; 790(1-2): 323-328.
PMID: 9593971; UI: 98256077.

 Gomez-Vargas M, et al.           
Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and
inhibits lipid peroxidation in different regions of the rat brain.
Brain Res. 1998 Apr 20; 790(1-2): 202-208.
PMID: 9593894; UI: 98256062.

 Andes GM.           
Mark Twain's cat.
Ann Intern Med. 1998 Jun 15; 128(12 Pt 1): 1043-1044. No abstract available.
PMID: 9625670; UI: 98273845.

 Muller T, et al.           
Selegiline as immunostimulant--a novel mechanism of action?
J Neural Transm Suppl. 1998; 52: 321-328.
PMID: 9564633; UI: 98225821.

 Sterling J, et al.           
(R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective
and potent inhibitors of monoamine oxidase B.
J Neural Transm Suppl. 1998; 52: 301-305.
PMID: 9564630; UI: 98225818.

 Gotz ME, et al.           
Chronic TVP-1012 (rasagiline) dose--activity response of monoamine oxidases A
and B in the brain of the common marmoset.
J Neural Transm Suppl. 1998; 52: 271-278.
PMID: 9564627; UI: 98225815.

 Richards JG, et al.           
Monoamine oxidases: from brain maps to physiology and transgenics to
pathophysiology.
J Neural Transm Suppl. 1998; 52: 173-187. Review.
PMID: 9564618; UI: 98225805.

 Naoi M, et al.           
Oxidation of N-methyl(R)salsolinol: involvement to neurotoxicity and
neuroprotection by endogenous catechol isoquinolines.
J Neural Transm Suppl. 1998; 52: 125-138.
PMID: 9564615; UI: 98225802.

 Magyar K, et al.           
The neuroprotective and neuronal rescue effects of (-)-deprenyl.
J Neural Transm Suppl. 1998; 52: 109-123. Review.
PMID: 9564614; UI: 98225801.

 Stern G.           
Neuroprotection by selegiline and other MAO inhibitors.
J Neural Transm Suppl. 1998; 52: 99-107. Review.
PMID: 9564613; UI: 98225800.

 Hocherman S, et al.           
Deprenyl monotherapy improves visuo-motor control in early parkinsonism.
J Neural Transm Suppl. 1998; 52: 63-69.
PMID: 9564608; UI: 98225795.

 Fahn S, et al.           
Experience with tranylcypromine in early Parkinson's disease.
J Neural Transm Suppl. 1998; 52: 49-61.
PMID: 9564607; UI: 98225794.

 Borroni E, et al.           
Mose Da Prada and the discovery of tolcapone.
J Neural Transm Suppl. 1998; 52: XIII-XVI. No abstract available.
PMID: 9564601; UI: 98225788.

 Parker WD Jr, et al.           
Mitochondrial dysfunction in idiopathic Parkinson disease.
Am J Hum Genet. 1998 Apr; 62(4): 758-762. Review.
PMID: 9529370; UI: 98198331.

 Katzen HL, et al.           
Age of disease onset influences cognition in Parkinson's disease.
J Int Neuropsychol Soc. 1998 May; 4(3): 285-290.
PMID: 9623003; UI: 98286206.

 Stern Y, et al.           
Prospective comparative study of the evolution of probable Alzheimer's disease
and Parkinson's disease dementia.
J Int Neuropsychol Soc. 1998 May; 4(3): 279-284.
PMID: 9623002; UI: 98286205.

 Bjugstad KB, et al.           
Preventive actions of a synthetic antioxidant in a novel animal model of AIDS
dementia.
Brain Res. 1998 Jun 8; 795(1-2): 349-357.
PMID: 9622673.

 Walker DG, et al.           
Immunohistochemical analyses of fibroblast growth factor receptor-1 in the
human substantia nigra. Comparison between normal and Parkinson's disease
cases.
Brain Res. 1998 Jun 1; 794(2): 181-187.
PMID: 9622624.

 Elsworth JD, et al.           
Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is
reversed by grafts of fetal ventral mesencephalon: an autoradiographic study.
Brain Res. 1998 Jun 8; 795(1-2): 55-62.
PMID: 9622593.

 Fitoussi N, et al.           
Dopamine turnover and metabolism in the striatum of parkinsonian rats grafted
with genetically-modified human astrocytes.
Neuroscience. 1998 Jul; 85(2): 405-413.
PMID: 9622240; UI: 98283583.

 Dunnett SB, et al.           
A lateralised grip strength test to evaluate unilateral nigrostriatal lesions
in rats.
Neurosci Lett. 1998 Apr 17; 246(1): 1-4.
PMID: 9622193; UI: 98283536.

 Bennett DA, et al.           
Parkinsonian signs and mortality from Alzheimer's disease.
Lancet. 1998 May 30; 351(9116): 1631. No abstract available.
PMID: 9620721; UI: 98282043.

 Heresco-Levy U, et al.           
The role of N-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission in
the pathophysiology and therapeutics of psychiatric syndromes.
Eur Neuropsychopharmacol. 1998 May; 8(2): 141-152.
PMID: 9619693; UI: 98280992.

 Rijken PM, et al.           
Clinical experience of rehabilitation therapists with chronic diseases: a
quantitative approach.
Clin Rehabil. 1998 Apr; 12(2): 143-150.
PMID: 9619656; UI: 98280955.

 Owen AM, et al.           
Abnormal basal ganglia outflow in Parkinson's disease identified with PET.
Implications for higher cortical functions.
Brain. 1998 May; 121( Pt 5): 949-965.
PMID: 9619196; UI: 98282955.

 Rogers RD, et al.           
Dissociating executive mechanisms of task control following frontal lobe
damage and Parkinson's disease.
Brain. 1998 May; 121( Pt 5): 815-842.
PMID: 9619187; UI: 98282946.

continued in part 2 of 2...